Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $679.29M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.29M
Average 0.45M
Big Five Numbers
Attovia Therapeutics, Inc. growth analysis
Start with the long-run numbers that show whether ATTO compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where ATTO earns its revenue, as reported in company filings
No segment data for this view.
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$61.5M. FCF conversion is 101.0% of net income. Operating cash flow was -$59.2M, with capex of -$2.3M. The largest bridge item is Capex at -$2.3M.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for ATTO.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for ATTO.
Competitor growth
How does Attovia Therapeutics, Inc. grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
Oruka Therapeutics, Inc. ORKA | $7.15B | — | — | — | —3 analysts |
AnaptysBio, Inc. ANAB | $1.38B | +29.6% | +25.6% | +183.6% | +11.7% (5yr)1 analysts |
MoonLake Immunotherapeutics MLTX | $1.06B | — | — | — | —4 analysts |
Alumis Inc. ALMS | $724.84M | — | — | — | +105.6% (5yr)5 analysts |
Aclaris Therapeutics, Inc. ACRS | $621.76M | — | +3.8% | -35.9% | +59.9% (5yr)5 analysts |
AgomAb Therapeutics N.V. American Depositary Shares AGMB | $313.22M | — | — | — | — |
Evommune, Inc. EVMN | $276.91M | — | — | — | -10.8% (5yr)3 analysts |
Q32 Bio Inc. QTTB | $260.64M | — | +81.9% | +100.7% | +23.9% (5yr)2 analysts |
Zura Bio Limited ZURA | $119.44M | — | — | — | —2 analysts |
Connect Biopharma Holdings Limited CNTB | $42.65M | — | — | — | +300.6% (5yr)3 analysts |
Questions
Growth questions
Common questions about ATTO's growth, answered from reported and forecast figures.
Is ATTO turning growth into profit?
The latest net margin is -4490.9%, which shows how much revenue became net income.
Continue the stock analysis
Jump to another research area for this company.